Summary: There is currently no established clinical evidence that GLP-1 medications directly treat or reduce hot flashes associated with menopause
Proper injection technique and site rotation reduce incidence significantly
It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Heatwole CR, Eichinger KJ, Friedman DI, Hilbert JE, Jackson CE, Logigian EL, Martens WB, McDermott MP, Pandya SK, Quinn C: Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1
Although the GSIS remained comparable in WT and Trpm5 / mouse islets, triagonist-induced GSIS was significantly reduced in Trpm5 / islets after 16 weeks on either LFD or HFD compared with controls (Fig
And future versions of these glucagon-like peptide-1 (GLP-1) medicines could be game-changers: In clinical trials, theyre showing to not only stave hunger, but improve the way your body breaks down sugar to boot
